Hamm and Skaar are among 120 voting members and 30 international members of the NAS whose elections were announced on April 29.

The findings of a new research study increase understanding of the molecular drivers of C. diff infection and point to novel therapeutic strategies aimed at a pathogen that causes about half a million infections in the U.S. each year.

Skaar, who directs the Vanderbilt Institute for Infection, Immunology and Inflammation, is being recognized for “pioneering work at the intersection of nutrition and infectious diseases."

The study findings point to the potential of interleukin-13 antibodies — approved for use in humans — as a treatment to protect against bacterial pneumonia in patients with zinc deficiency.

Scientists from Vanderbilt University and Vanderbilt University Medical Center led several activities to illustrate the important roles that microorganisms play in the environment and human health.

The seventh annual event invites students to conduct science experiments, join in hands-on activities, and win prizes and giveaways.

Senior author Mary Philip, MD, PhD, associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation, talks about her Journal for ImmunoTherapy of Cancer study. The findings support further vaccine investigation to make long-term, progression-free survival a reality for more cancer patients.